170 related articles for article (PubMed ID: 21728901)
1. Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer.
Abou-Zeid AA; Azzam AZ; Kamel NA
Scand J Clin Lab Invest; 2011 Nov; 71(7):542-7. PubMed ID: 21728901
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation profile of ovarian epithelial neoplasms.
Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
[TBL] [Abstract][Full Text] [Related]
3. [Gene methylation in stool for the screening of colorectal cancer and pre-malignant lesions].
Kang YP; Cao FA; Chang WJ; Lou Z; Wang H; Wu LL; Fu CG; Cao GW
Zhonghua Wei Chang Wai Ke Za Zhi; 2011 Jan; 14(1):52-6. PubMed ID: 21271382
[TBL] [Abstract][Full Text] [Related]
4. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas.
Furlan D; Carnevali I; Marcomini B; Cerutti R; Dainese E; Capella C; Riva C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3329-36. PubMed ID: 16740754
[TBL] [Abstract][Full Text] [Related]
5. GnRH-II mRNA expression in tumor tissue and peripheral blood mononuclear cells (PBMCs) in patients with malignant and benign ovarian tumors.
Serin IS; Tanriverdi F; Ata CD; Akalin H; Ozcelik B; Ozkul Y; Kelestimur F
Eur J Obstet Gynecol Reprod Biol; 2010 Mar; 149(1):92-6. PubMed ID: 20018426
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression.
Wang YQ; Yan Q; Zhang JR; Li SD; Yang YX; Wan XP
J Obstet Gynaecol Res; 2013 Feb; 39(2):549-54. PubMed ID: 23006047
[TBL] [Abstract][Full Text] [Related]
7. CDKN2A promoter methylation in gastric adenocarcinomas: clinical variables.
Vo QN; Geradts J; Boudreau DA; Bravo JC; Schneider BG
Hum Pathol; 2002 Dec; 33(12):1200-4. PubMed ID: 12514789
[TBL] [Abstract][Full Text] [Related]
8. Decreased expression of RIZ1 and its clinicopathological significance in epithelial ovarian carcinoma: correlation with epigenetic inactivation by aberrant DNA methylation.
Akahira J; Suzuki F; Suzuki T; Miura I; Kamogawa N; Miki Y; Ito K; Yaegashi N; Sasano H
Pathol Int; 2007 Nov; 57(11):725-33. PubMed ID: 17922684
[TBL] [Abstract][Full Text] [Related]
9. Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer.
Czekierdowski A; Czekierdowska S; Szymanski M; Wielgos M; Kaminski P; Kotarski J
Neuro Endocrinol Lett; 2006 Oct; 27(5):609-13. PubMed ID: 17159813
[TBL] [Abstract][Full Text] [Related]
10. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients.
Harden SV; Tokumaru Y; Westra WH; Goodman S; Ahrendt SA; Yang SC; Sidransky D
Clin Cancer Res; 2003 Apr; 9(4):1370-5. PubMed ID: 12684406
[TBL] [Abstract][Full Text] [Related]
11. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C
Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049
[TBL] [Abstract][Full Text] [Related]
12. A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA.
Zhang Q; Hu G; Yang Q; Dong R; Xie X; Ma D; Shen K; Kong B
Gynecol Oncol; 2013 Jul; 130(1):132-9. PubMed ID: 23623832
[TBL] [Abstract][Full Text] [Related]
13. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
14. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma.
Shigemasa K; Hu C; West CM; Clarke J; Parham GP; Parmley TH; Korourian S; Baker VV; O'Brien TJ
J Soc Gynecol Investig; 1997; 4(2):95-102. PubMed ID: 9101469
[TBL] [Abstract][Full Text] [Related]
15. Microvessel density and CpG island methylation of the THBS2 gene in malignant ovarian tumors.
Czekierdowski A; Czekierdowska S; Danilos J; Czuba B; Sodowski K; Sodowska H; Szymanski M; Kotarski J
J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():53-65. PubMed ID: 18955754
[TBL] [Abstract][Full Text] [Related]
16. Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.
Kirsch M; Mörz M; Pinzer T; Schackert HK; Schackert G
Genes Chromosomes Cancer; 2009 Feb; 48(2):143-54. PubMed ID: 18973139
[TBL] [Abstract][Full Text] [Related]
17. CDKN2A gene inactivation in epithelial sporadic ovarian cancer.
Niederacher D; Yan HY; An HX; Bender HG; Beckmann MW
Br J Cancer; 1999 Aug; 80(12):1920-6. PubMed ID: 10471040
[TBL] [Abstract][Full Text] [Related]
18. [Inactivation of CDKN2A gene (p16) in gallbladder carcinoma].
Roa JC; Vo Q; Araya JC; Villaseca M; Guzmán P; Ibacache GS; de Aretxabala X; Roa I
Rev Med Chil; 2004 Nov; 132(11):1369-76. PubMed ID: 15693199
[TBL] [Abstract][Full Text] [Related]
19. P16/CDKN2A and Ki-67 enhance the detection of anal intraepithelial neoplasia and condyloma and correlate with human papillomavirus detection by polymerase chain reaction.
Pirog EC; Quint KD; Yantiss RK
Am J Surg Pathol; 2010 Oct; 34(10):1449-55. PubMed ID: 20871219
[TBL] [Abstract][Full Text] [Related]
20. Aberrant methylation of the CDKN2a/p16INK4a gene promoter region in preinvasive bronchial lesions: a prospective study in high-risk patients without invasive cancer.
Lamy A; Sesboüé R; Bourguignon J; Dautréaux B; Métayer J; Frébourg T; Thiberville L
Int J Cancer; 2002 Jul; 100(2):189-93. PubMed ID: 12115568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
